EO 2: Posts Will Offer Services to Consumers That Facilitate Access to GLP-1 Medications From Places Perceived to be Outside of Traditional Health Care Settings (eg, Primary Care, Obesity Medicine, Endocrinology, or Other Specialty Care). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.